AZD1152 in Patients With Advanced Solid Malignancies
AZD1152 in Patients With Advanced Solid Malignancies
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152
 when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2
 consecutive days every 14 days in patients with advanced solid malignancies.
Inclusion Criteria:

 -  Histological or cytological confirmation of a solid, malignant tumour

 -  At least one measurable or non-measurable site of disease as defined by Response
 Evaluation Criteria in Solid Tumors (RECIST) criteria.

 Exclusion Criteria:

 -  Participation in an investigational drug study within the 21 days prior to therapy or
 those who have not recovered from the effects of an investigational study drug

 -  Recent major surgery within 4 weeks prior to entry into the study